Cabazitaxel

Nature Reviews Drug Discovery

Volumn 9, Issue 9, 2010, Pages 677-678

  Galsky, Matthew D ^a   Dritselis, Argyris ^b   Kirkpatrick, Peter ^c   Oh, William K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANTIANDROGEN; CABAZITAXEL; DOCETAXEL; JEVTANA; MDV 3100; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISONE; PROVENGE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TAXOID;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURVIVAL TIME; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; MALE; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; MALE; PREDNISONE; PROSTATIC NEOPLASMS; TAXOIDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77956319059     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3254     Document Type: Review

References (17)

1. Jemal, A. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Oh, W. K. & Schurko, B. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Clin. Pract. Oncol. 5, 506-507 (2008).
3. Higano, C. S. et al. Sipuleucel-T. Nature Rev. Drug Discov. 9, 513-514 (2010).
4. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer 4, 253-265 (2004).
5. Mita, A. C. et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 15, 723-730 (2009).
6. Pivot, X. et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 19,1547-1552 (2008).
7. US Food and Drug Administration. FDA labelling information - Jevtana (cabazitaxel). FDA website [online], http://www.accessdata.fda.gov/drugsatfda- docs/label/2010/201023lbl.pdf (2010).
8. De Bono, J. S. et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castrationresistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J. Clin. Oncol. 28 (Suppl. 15), 4508 (2010).
9. Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447-4454 (2008).
10. Locke, J. A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407-6415 (2008).
11. Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496-1501 (2010).
12. Reid, A. H. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28,1489-1495 (2010).
13. Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446 (2010).
14. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009).
15. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
16. IMS MIDAS (IMS Health, 2010).
17. Hauber, A. et al. JP Morgan Europe Research (JP Morgan Cazenove, 21 May 2010).